## Christian la FougÃ"re

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1206044/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology, 2016, 18, 1199-1208.	1.2	566
2	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
3	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
4	Real versus imagined locomotion: A [18F]-FDG PET-fMRI comparison. NeuroImage, 2010, 50, 1589-1598.	4.2	342
5	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	6.4	237
6	Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 767-773.	1.9	234
7	Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro-Oncology, 2011, 13, 806-819.	1.2	225
8	Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology, 2011, 13, 307-316.	1.2	215
9	[18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology, 2013, 15, 341-351.	1.2	192
10	PET and SPECT in epilepsy: A critical review. Epilepsy and Behavior, 2009, 15, 50-55.	1.7	171
11	The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 2003, 27, 605-613.	6.1	168
12	MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1021-1029.	6.4	160
13	Biological tumor volume in <sup>18</sup> FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 2015, 84, 710-719.	1.1	144
14	Prognostic Significance of Dynamic <sup>18</sup> F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. Journal of Nuclear Medicine, 2015, 56, 9-15.	5.0	144
15	Two decades of SPECT/CT – the coming of age of a technology: An updated review of literature evidence. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1990-2012.	6.4	139
16	In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using <sup>68</sup> Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors. Journal of Nuclear Medicine, 2010, 51, 193-197.	5.0	137
17	Hepatic Yttrium-90 Radioembolization of Chemotherapy-refractory Colorectal Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2008, 19, 1187-1195.	0.5	130
18	FET–PET for malignant glioma treatment planning. Radiotherapy and Oncology, 2011, 99, 44-48.	0.6	125

Christian la FougÃ<sup>"</sup>re

#	Article	IF	CITATIONS
19	Dynamic <sup>18</sup> F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. Journal of Nuclear Medicine, 2014, 55, 198-203.	5.0	123
20	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 581-592.	10.7	121
21	Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. International Journal of Radiation Oncology Biology Physics, 2012, 82, 67-76.	0.8	119
22	Where in-vivo imaging meets cytoarchitectonics: The relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. NeuroImage, 2011, 56, 951-960.	4.2	113
23	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiotherapy and Oncology, 2017, 124, 526-532.	0.6	107
24	Radioembolization in Patients with Hepatic Metastases from Breast Cancer. Journal of Vascular and Interventional Radiology, 2008, 19, 683-690.	0.5	103
25	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
26	Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-Oncology, 2012, 14, 1473-1480.	1.2	91
27	Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1105-1114.	6.4	88
28	Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1417-1425.	6.4	85
29	In vivo visualization of prostate-specific membrane antigen in glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 170-171.	6.4	85
30	Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology, 2011, 77, 101-109.	1.1	84
31	Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 123-132.	6.4	81
32	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). European Radiology, 2018, 28, 4086-4101.	4.5	80
33	Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 428-431.	3.2	72
34	Functional disturbance of the locomotor network in progressive supranuclear palsy. Neurology, 2013, 80, 634-641.	1.1	69
35	Dynamic <sup>18</sup> <scp>Fâ€FET PET</scp> in suspected <scp>WHO</scp> grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 2015, 136, 2132-2145.	5.1	68
36	Functional Representation of Olfactory Impairment in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 581-591.	2.6	66

#	Article	IF	CITATIONS
37	Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. Journal of Neuro-Oncology, 2014, 117, 337-345.	2.9	66
38	Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nuclear Medicine Communications, 2006, 27, 733-737.	1.1	63
39	Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1938-1946.	6.4	60
40	N-Acetyl-L-Leucine Accelerates Vestibular Compensation after Unilateral Labyrinthectomy by Action in the Cerebellum and Thalamus. PLoS ONE, 2015, 10, e0120891.	2.5	60
41	Correlation of Brown Adipose Tissue with Other Body Fat Compartments and Patient Characteristics. Academic Radiology, 2018, 25, 102-110.	2.5	57
42	Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology, 2015, 17, 595-608.	2.6	56
43	The Value of the Dopamine D <sub>2/3</sub> Receptor Ligand <sup>18</sup> F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. Journal of Nuclear Medicine, 2010, 51, 581-587.	5.0	51
44	Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochirurgica, 2014, 156, 1427-1440.	1.7	51
45	Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. Neuropsychopharmacology, 2017, 42, 606-614.	5.4	51
46	FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiotherapy and Oncology, 2012, 104, 78-82.	0.6	50
47	[ <sup>18</sup> F]fallypride PET measurement of striatal and extrastriatal dopamine D <sub>2/3</sub> receptor availability in recently abstinent alcoholics. Addiction Biology, 2012, 17, 490-503.	2.6	50
48	Sequential [18F]FDG µPET whole-brain imaging of central vestibular compensation: a model of deafferentation-induced brain plasticity. Brain Structure and Function, 2016, 221, 159-170.	2.3	49
49	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. NeuroImage, 2010, 49, 1406-1415.	4.2	47
50	PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 822-831.	6.4	47
51	Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 115-121.	3.2	46
52	Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. Pharmacopsychiatry, 2008, 41, 169-175.	3.3	46
53	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	6.4	46
54	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i> <sup>18</sup> F-FDG-PET. Theranostics, 2020, 10, 925-937.	10.0	46

Christian la FougÃ<sup>¨</sup>re

#	Article	IF	CITATIONS
55	Imaging of Pâ€glycoprotein–mediated pharmacoresistance in the hippocampus: Proofâ€ofâ€concept in a chronic rat model of temporal lobe epilepsy. Epilepsia, 2010, 51, 1780-1790.	5.1	45
56	Independent attenuation correction of whole body [18F]FDG-PET using a deep learning approach with Generative Adversarial Networks. EJNMMI Research, 2020, 10, 53.	2.5	44
57	Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naÃ⁻ve schizophrenic patients. Schizophrenia Research, 2008, 101, 133-141.	2.0	43
58	CT imaging of bone and bone marrow infiltration in malignant melanoma—Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. European Journal of Radiology, 2016, 85, 732-738.	2.6	43
59	Pathological ponto-cerebello-thalamo-cortical activations in primary orthostatic tremor during lying and stance. Brain, 2017, 140, 83-97.	7.6	43
60	The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. Journal of Psychopharmacology, 2005, 19, 488-493.	4.0	42
61	Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World Journal of Biological Psychiatry, 2006, 7, 152-157.	2.6	42
62	Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? – Variability induced by different SUV measurements and varying reconstruction methods. European Journal of Radiology, 2015, 84, 158-162.	2.6	42
63	Defining optimal tracer activities in pediatric oncologic whole-body 18F-FDG-PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2283-2289.	6.4	42
64	Anisotropy of Human Horizontal and Vertical Navigation in Real Space: Behavioral and PET Correlates. Cerebral Cortex, 2016, 26, 4392-4404.	2.9	42
65	FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer´s disease. Journal of Psychiatric Research, 2010, 44, 462-469.	3.1	40
66	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
67	Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clinical Cancer Informatics, 2020, 4, 1027-1038.	2.1	39
68	F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers. Journal of Computer Assisted Tomography, 2007, 31, 629-634.	0.9	38
69	Segmentation-Based Attenuation Correction in Positron Emission Tomography/Magnetic Resonance. Investigative Radiology, 2015, 50, 339-346.	6.2	38
70	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 482-488.	6.4	37
71	A Prospective Study of Quantitative SPECT/CT for Evaluation of Lung Shunt Fraction Before SIRT of Liver Tumors. Journal of Nuclear Medicine, 2018, 59, 1366-1372.	5.0	37
72	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic <sup>18</sup> F-FMISO PET for Head and Neck Cancer Radiotherapy. Journal of Nuclear Medicine, 2019, 60, 1698-1704.	5.0	37

#	Article	IF	CITATIONS
73	[ <sup>18</sup> F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. Molecular Imaging, 2013, 12, 7290.2012.00027.	1.4	36
74	Improved work-up procedure for the production of [18F]flumazenil and first results of its use with a high-resolution research tomograph in human stroke. Nuclear Medicine and Biology, 2009, 36, 721-727.	0.6	35
	Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in) Tj ETQq1	1 0.78431	4 rgBT /Ove
75	prior use of chemotherapy in routine clinical practice. European Journal of Nuclear Medicine and Molecular Imaging. 2019. 46. 1102-1110.	6.4	35
76	Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET–PET. Journal of Neuro-Oncology, 2012, 110, 389-395.	2.9	34
77	The mixed blessing of treating symptoms in acute vestibular failure — Evidence from a 4-aminopyridine experiment. Experimental Neurology, 2014, 261, 638-645.	4.1	34
78	Prostate-specific Membrane Antigen Positron Emission Tomography–detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	3.1	34
79	Clinical validation of the gated blood pool SPECT QBS® processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. International Journal of Cardiovascular Imaging, 2006, 22, 407-416.	1.5	33
80	Impulsivity is related to striatal dopamine transporter availability in healthy males. Psychiatry Research - Neuroimaging, 2013, 211, 251-256.	1.8	33
81	Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric <i>In Vivo</i> Imaging: A Translational Study. Cancer Research, 2016, 76, 5512-5522.	0.9	33
82	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. Clinical Nuclear Medicine, 2018, 43, 895-898.	1.3	33
83	Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis. JACC: Cardiovascular Imaging, 2022, 15, 445-456.	5.3	33
84	4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. Journal of Neurology, 2013, 260, 321-323.	3.6	32
85	Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients. Radiotherapy and Oncology, 2018, 128, 485-491.	0.6	32
86	Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 776-787.	6.4	32
87	Effects of acute detoxification of the herbal blend â€~Spice Gold' on dopamine D2/3 receptor availability: A [18F]fallypride PET study. European Neuropsychopharmacology, 2013, 23, 1606-1610.	0.7	31
88	Effects of a 6-Month Cognitive Intervention Program on Brain Metabolism in Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 695-706.	2.6	30
89	Improving CT-Based PET Attenuation Correction in the Vicinity of Metal Implants by an Iterative Metal Artifact Reduction Algorithm of CT Data and Its Comparison to Dual-Energy–Based Strategies. Investigative Radiology, 2017, 52, 61-65.	6.2	30
90	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. Neuro-Oncology, 2019, 21, 274-284.	1.2	30

Christian la FougÃ"re

#	Article	IF	CITATIONS
91	Practice-based evidence for the clinical benefit of PET/CT—results of the first oncologic PET/CT registry in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 54-64.	6.4	30
92	D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. Journal of Nuclear Medicine, 2005, 46, 1028-33.	5.0	30
93	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	6.4	29
94	Intention-to-Treat Analysis of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	5.0	29
95	Multiparametric analysis of bone marrow in cancer patients using simultaneous PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric data. Journal of Magnetic Resonance Imaging, 2015, 42, 1048-1056.	3.4	28
96	An IgCâ€based bispecific antibody for improved dual targeting in PSMAâ€positive cancer. EMBO Molecular Medicine, 2021, 13, e11902.	6.9	28
97	Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients. Medical Physics, 2017, 44, 2358-2368.	3.0	27
98	Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [1231]I²-CIT SPECT study. European Neuropsychopharmacology, 2015, 25, 873-881.	0.7	26
99	Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiologia Medica, 2018, 123, 860-870.	7.7	26
100	ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. Dialogues in Clinical Neuroscience, 2006, 8, 29-36.	3.7	26
101	Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echocardiography: A comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT. European Journal of Echocardiography, 2007, 9, 494-500.	2.3	25
102	Towards tracer dose reduction in PET studies: Simulation of dose reduction by retrospective randomized undersampling of list-mode data. Hellenic Journal of Nuclear Medicine, 2016, 19, 15-8.	0.3	25
103	Combined unsupervised–supervised classification of multiparametric PET/MRI data: application to prostate cancer. NMR in Biomedicine, 2015, 28, 914-922.	2.8	24
104	Clinical use of cardiac PET/MRI: current state-of-the-art and potential future applications. Japanese Journal of Radiology, 2018, 36, 313-323.	2.4	24
105	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. Neurology, 2020, 94, e861-e873.	1.1	24
106	Central Insulin Modulates Dopamine Signaling in the Human Striatum. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2949-2961.	3.6	24
107	[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Molecular Imaging, 2013, 12, 137-47.	1.4	24
108	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [1231]IBZM SPECT. Psychiatry Research - Neuroimaging, 2009, 173, 183-189.	1.8	23

#	Article	IF	CITATIONS
109	Myocardial Perfusion Imaging is Feasible for Infarct Size Quantification in Mice Using a Clinical Single-photon Emission Computed Tomography System Equipped with Pinhole Collimators. Molecular Imaging and Biology, 2010, 12, 427-434.	2.6	23
110	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1312-1318.	6.4	23
111	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. Acta Oncológica, 2017, 56, 1571-1576.	1.8	23
112	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	6.4	23
113	Methylphenidate Effects on Brain Activity as a Function of SLC6A3 Genotype and Striatal Dopamine Transporter Availability. Neuropsychopharmacology, 2015, 40, 736-745.	5.4	22
114	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. Acta Oncológica, 2015, 54, 1364-1369.	1.8	22
115	Simulation of Tracer Dose Reduction in 18F-FDG PET/MRI: Effects on Oncologic Reading, Image Quality, and Artifacts. Journal of Nuclear Medicine, 2017, 58, 1699-1705.	5.0	22
116	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiotherapy and Oncology, 2022, 171, 30-36.	0.6	22
117	Surrogate markers for cerebral blood flow correlate with [ <sup>18</sup> F]â€fallypride binding potential at dopamine D <sub>2/3</sub> receptors in human striatum. Synapse, 2013, 67, 199-203.	1.2	21
118	Comparison of Positron Emission Tomography Quantification Using Magnetic Resonance– and Computed Tomography–Based Attenuation Correction in Physiological Tissues and Lesions. Investigative Radiology, 2016, 51, 66-71.	6.2	21
119	Is there a link between very early changes of primary and secondary lymphoid organs in <sup>18</sup> F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
120	Pediatric Oncologic Imaging: A Key Application of Combined PET/MRI. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 188, 359-364.	1.3	20
121	Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. Acta Oncológica, 2017, 56, 1577-1582.	1.8	20
122	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	2.6	20
123	<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup> Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. Journal of Nuclear Medicine, 2022, 63, 410-414.	5.0	19
124	Impact of <sup>18</sup> F-FET PET/MRI on Clinical Management of Brain Tumor Patients. Journal of Nuclear Medicine, 2022, 63, 522-527.	5.0	19
125	Bilateral temporal lobe epilepsy confirmed with intracranial EEG in chorea-acanthocytosis. Seizure: the Journal of the British Epilepsy Association, 2011, 20, 340-342.	2.0	18
126	Determination of Split Renal Function Using Dynamic CT-Angiography: Preliminary Results. PLoS ONE, 2014, 9, e91774.	2.5	18

## Christian la FougÃ<sup>¨</sup>re

#	Article	IF	CITATIONS
127	Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1511-1519.	6.4	18
128	Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers?. European Journal of Radiology, 2018, 99, 94-102.	2.6	18
129	Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. World Journal of Urology, 2020, 38, 2513-2521.	2.2	17
130	Impact of PET/CT on clinical management in patients with cancer of unknown primary—a PET/CT registry study. European Radiology, 2020, 30, 1325-1333.	4.5	17
131	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
132	Independent brain F-FDG PET attenuation correction using a deep learning approach with Generative Adversarial Networks. Hellenic Journal of Nuclear Medicine, 2019, 22, 179-186.	0.3	17
133	Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1852-1863.	6.4	16
134	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget, 2017, 8, 44131-44140.	1.8	16
135	Effects of peripheral vascular intervention on ischemia-modified albumin. Coronary Artery Disease, 2007, 18, 375-379.	0.7	15
136	Pericervical Injection of 99mTc-Nanocolloid Is Superior to Peritumoral Injection for Sentinel Lymph Node Detection of Endometrial Cancer in SPECT/CT. Clinical Nuclear Medicine, 2016, 41, 927-932.	1.3	15
137	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. Frontiers in Neurology, 2017, 8, 665.	2.4	15
138	The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 48-54.	5.0	15
139	Abstract 1146: [18F]FPyGal: A novel ß-galactosidase specific PET tracer forin vivoimaging of tumor senescence. , 2019, , .		15
140	Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. NeuroImage: Clinical, 2016, 12, 41-46.	2.7	14
141	Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 183-191.	3.2	13
142	Radius dependence of FP-CIT quantification: a Monte Carlo-based simulation study. Annals of Nuclear Medicine, 2014, 28, 103-111.	2.2	13
143	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	6.4	13
144	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. Cancer Imaging, 2020, 20, 44.	2.8	13

#	Article	IF	CITATIONS
145	Erroneous cardiac ECG-gated PET list-mode trigger events can be retrospectively identified and replaced by an offline reprocessing approach: first results in rodents. Physics in Medicine and Biology, 2013, 58, 7937-7959.	3.0	12
146	Assessment of cerebral dopamine D 2 / 3 -receptors in patients with bilateral vestibular failure. Journal of Vestibular Research: Equilibrium and Orientation, 2014, 24, 403-413.	2.0	12
147	Distortion correction of diffusion-weighted magnetic resonance imaging of the head and neck in radiotherapy position. Acta OncolÃ <sup>3</sup> gica, 2017, 56, 1659-1663.	1.8	12
148	Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients. BioMed Research International, 2017, 2017, 1-10.	1.9	12
149	Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest. Neuroradiology, 2018, 60, 381-389.	2.2	12
150	Value of CT iterative metal artifact reduction in PET/CT—clinical evaluation in 100 patients. British Journal of Radiology, 2019, 92, 20180756.	2.2	12
151	Machine learning identifies stroke features between species. Theranostics, 2021, 11, 3017-3034.	10.0	12
152	Ictal SPECT in Sturge-Weber syndrome. Epilepsy Research, 2008, 78, 240-243.	1.6	11
153	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	2.8	11
154	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. Clinical Neurology and Neurosurgery, 2014, 122, 113-115.	1.4	10
155	SUV-quantification of physiological lung tissue in an integrated PET/MR-system: Impact of lung density and bone tissue. PLoS ONE, 2017, 12, e0177856.	2.5	10
156	Compensation for cranial spillâ€in into the cerebellum improves quantitation of striatal dopamine D <sub>2/3</sub> receptors in rats with prolonged [ <sup>18</sup> F]â€DMFP infusions. Synapse, 2012, 66, 705-713.	1.2	9
157	Voxel-wise correlation of functional imaging parameters in HNSCC patients receiving PET/MRI in an irradiation setup. Strahlentherapie Und Onkologie, 2018, 194, 719-726.	2.0	9
158	<sup>68</sup> Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta Oncológica, 2020, 59, 149-156.	1.8	9
159	Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer's disease with FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2370-2379.	6.4	8
160	PET/MRI and genetic intrapatient heterogeneity in head and neck cancers. Strahlentherapie Und Onkologie, 2020, 196, 542-551.	2.0	8
161	<sup>131</sup> I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors. Journal of Nuclear Medicine, 2022, 63, 205-211.	5.0	8
162	Response to "Reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al Neuro-Oncology, 2013, 15, 814-815.	1.2	7

Christian la FougÃ<sup>"</sup>re

#	Article	IF	CITATIONS
163	Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga–Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2017, 42, 717-718.	1.3	7
164	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. PLoS ONE, 2019, 14, e0216111.	2.5	7
165	Impact of diverse chemotherapeutic agents and external factors on activation of brown adipose tissue in a large patient collective. Scientific Reports, 2019, 9, 1901.	3.3	7
166	Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM). European Journal of Hybrid Imaging, 2018, 2, .	1.5	6
167	Lymph Node Staging with a Combined Protocol of <sup>18</sup> F-FDG PET/MRI and Sentinel Node SPECT/CT: A Prospective Study in Patients with FIGO I/II Cervical Carcinoma. Journal of Nuclear Medicine, 2021, 62, 1062-1067.	5.0	6
168	Intramedullary Pilomyxoid Astrocytoma with Intracerebral Metastasis Exhibiting Oligoden-Droglioma-Like Features. Rare Tumors, 2012, 4, 92-95.	0.6	5
169	Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms. Anticancer Research, 2018, 38, 4047-4056.	1.1	5
170	Influence of 99m-Tc-Nanocolloid Activity Concentration on Sentinel Lymph Node Detection in Endometrial Cancer: A Quantitative SPECT/CT Study. Diagnostics, 2020, 10, 700.	2.6	5
171	Determinants of activity of brown adipose tissue in lymphoma patients. Scientific Reports, 2020, 10, 21802.	3.3	5
172	Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2313-2321.	6.4	5
173	Impact of <sup>18</sup> F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. BJR   Open, 2021, 3, 20210008.	0.6	5
174	Hybrid MR-PET in Neuroimaging. Clinical Neuroradiology, 2015, 25, 275-281.	1.9	4
175	Assessment of the parenchymal blood volume by C-arm computed tomography for radioembolization dosimetry. European Journal of Radiology, 2016, 85, 1525-1531.	2.6	4
176	Nicotine–dopamine-transporter interactions during reward-based decision making. European Neuropsychopharmacology, 2016, 26, 938-947.	0.7	4
177	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
178	Striatal Dopamine Transporter Binding in Adults With ADHD. American Journal of Psychiatry, 2012, 169, 665-665.	7.2	3
179	Derivation of a respiration trigger signal in small animal list-mode PET based on respiration-induced variations of the ECG signal. Journal of Nuclear Cardiology, 2016, 23, 73-83.	2.1	3
180	Assessment of Skeletal Tumor Load in Metastasized Castration-Resistant Prostate Cancer Patients: A Review of Available Methods and an Overview on Future Perspectives. Bioengineering, 2018, 5, 58.	3.5	3

Christian la Fougère

#	Article	IF	CITATIONS
181	Impact of PET/CT on management of patients with esophageal cancer – results from a PET/CT registry study. European Journal of Radiology, 2021, 136, 109524.	2.6	3
182	Abstract LB-369: <i>In vivo i</i> maging of tumor senescence with a novel beta-galactosidase specific PET tracer. Cancer Research, 2018, 78, LB-369-LB-369.	0.9	3
183	3D-OSEM and FP-CIT SPECT quantification. Nuclear Medicine Communications, 2013, 34, 971-977.	1.1	2
184	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 52-59.	2.9	2
185	Comprehensive metabolic and morphologic disease characterization in systemic sclerosis: initial results using combined positron emission tomography and magnetic resonance imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 207-215.	0.7	2
186	Correlation of C-arm CT acquired parenchymal blood volume (PBV) with 99mTc-macroaggregated albumin (MAA) SPECT/CT for radioembolization work-up. PLoS ONE, 2020, 15, e0244235.	2.5	2
187	Evaluation of contrast medium enhancement and [18F]-FDG uptake of liver metastasis in PET/CT prior to therapy. European Journal of Radiology, 2012, 81, 652-657.	2.6	1
188	Computed diffusion weighted imaging (cDWI) and voxelwise-computed diffusion weighted imaging (vcDWI) for oncologic liver imaging: A pilot study. European Journal of Radiology Open, 2018, 5, 108-113.	1.6	1
189	Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images. Cancers, 2019, 11, 869.	3.7	1
190	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. European Journal of Radiology, 2020, 131, 109242.	2.6	1
191	18F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatment—A Case Report. Frontiers in Oncology, 2021, 11, 700397.	2.8	1
192	Transitioning to whole-body SPECT/CT in prostate cancer staging: aÂnew concept for a better imaging workflow. Nuklearmedizin - NuclearMedicine, 2019, 58, 451-459.	0.7	1
193	PET/MR in Oncology. Current Radiology Reports, 2015, 3, 1.	1.4	0
194	Ictal SPECT reveals different epileptogenic zones in frontal lobe epilepsy. Epileptic Disorders, 2018, 20, 447-450.	1.3	0
195	MNGI-11. LONGITUDINAL GENOMIC ANALYSIS OF SPORADIC MENINGIOMAS WITH MULTIPLE RECURRENCES. Neuro-Oncology, 2018, 20, vi150-vi150.	1.2	0
196	Value of 18F-PSMA-PET/MRI for Assessment of Recurring Ranula. Diagnostics, 2021, 11, 1462.	2.6	0
197	Abstract 3034:18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs. , 2018, , .		0
198	Abstract 658: Translational theranostic imaging of lymphoma using radiolabeled αCD19-antibodies. , 2018, , .		0

#	Article	IF	CITATIONS
199	1798-P: Insulin Modulates Dopaminergic Tone in the Human Brain—A Combined PET/MRI Study. Diabetes, 2019, 68, .	0.6	0
200	Title is missing!. , 2020, 15, e0244235.		0
201	Title is missing!. , 2020, 15, e0244235.		0
202	Title is missing!. , 2020, 15, e0244235.		0
203	Title is missing!. , 2020, 15, e0244235.		0
204	Abstract LB058: Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer. Cancer Research, 2022, 82, LB058-LB058.	0.9	0